Adeia Inc. reported a decline in Q3 2026 revenue to $80.2 million and a drop in EBITDA margin to 46%, driven by delays in media licensing agreements. The company lowered its 2026 revenue guidance due to these setbacks, despite strong recurring revenue. Adeia's future growth hinges on finalizing new licensing deals and semiconductor opportunities expected after 2027. Although the valuation is more reasonable at 10.2x EV/EBITDA, weak near-term growth and negative earnings per share trends limit the appeal for new investors.
Adeia Inc.'s recent revenue and margin challenges provide context for readers following technology stocks. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 04, 2026 21:31 WIB: Among 150 priced US Technology stocks tradable on Pluang, 94 rose and 55 fell today. Notable movers include ANET at USD 182.10 with a 7.17% increase and 92% sell order activity, DDOG at USD 206.46 down 6.38% with 100% buy order activity, and FIRY at USD 13.28 up 6.33% with 100% sell order activity.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
